2022 Revenues ($USD) : $274,329,000
2022 R&D spend : $48,506,000
2022 Number of Employees : 875
Fiscal Year End : 12/31/2021
Company CEO : Michael Carrel, president and CEO

AtriCure specializes in treating atrial fibrillation. The Mason, Ohio-based company’s Isolator Synergy ablation system has won FDA approval for treating persistent AFib. In April 2022, the company debuted its EnCompass Clamp as part of its Isolator Synergy ablation system. In addition, AtriCure’s AtriClip left atrial appendage exclusion system products are popular LAA management devices. Its Hybrid AF therapy is a minimally invasive procedure for persistent AFib patients, while its cryoICE cryoSPHERE probe is indicated for temporary ablation of peripheral nerves to block pain in cardiac and thoracic procedures. –BB